Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/Safety of ABT-450/r/ABT-267 + ABT-333 in Healthy Chinese Subjects
NCT02534870Phase 1Completed
- Sponsor
- AbbVie Inc.
- Start
- Sep 2015
- Primary completion
- Sep 2015
- Modality
- Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of paritaprevir, ombitasvir and dasabuvir in chronic hepatitis C (CHC), sponsored by AbbVie Inc. Primary endpoints: Maximum Plasma Concentration at Day 14, Time to Maximum Plasma Concentration at Day 14 and 4 more. Started Sep 2015; status: completed.
02
Drugs
paritaprevirombitasvirdasabuvir
03
Conditions
chronic hepatitis C (CHC)
Beyond the preview
Go deeper on NCT02534870.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02534870.